News & Events

Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting

Substantial, dose-dependent reductions in serum hepcidin and increases in serum iron Hematologic response demonstrated by increased hemoglobin levels and reduction in transfusion burden DISC-0974 was generally well-tolerated at all evaluated doses WATERTOWN, Mass., Dec.

More News

Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

WATERTOWN, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery,...

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

WATERTOWN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery,...

Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones

Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and subsequently was...